Searchable abstracts of presentations at key conferences in endocrinology

ea0081p169 | Pituitary and Neuroendocrinology | ECE2022

Identification of a novel SSTR3 full agonist and its activity in non-functioning pituitary adenoma model

Modena Daniela , Luisa Moras Maria , Sandrone Giovanni , Stevenazzi Andrea , Vergani Barbara , Dasgupta Pooja , Kliewer Andrea , Gulde Sebastian , Schillmaier Mathias , Luque Raul M. , Schulz Stefan , Pellegata Natalia , Steinkuhler Christian

Non-functioning pituitary adenomas (NFPAs), mainly gonadotroph pituitary adenomas (GPAs), are the second most common type of PAs. Given the lack of symptoms secondary to hormone hypersecretion, NFPAs are often diagnosed when they cause mass effects. At this stage they are invasive (50% of cases), they cannot be completely resected and often recur. Despite their frequency, no standard of care drug treatment currently exists for these tumors. SSAs (somatostatin agonists) like oc...

ea0081oc7.6 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

A tumor-borne Angpt2/Tie2 autostimulatory loop controls tumorigenesis

Pellegata Natalia , Minaskan Ninelia , Gulde Sebastian , Mohr Hermine , Geppert Julia , Rohm Maria , Vitale Giovanni , Gaudenzi Germano , Dicitore Alessandra , Franz Schilling , Schillmaier Mathias , Eisenhofer Graeme , Herzig Stephan , Roncaroli Federico , Honegger Jurgen

Background: Invasive nonfunctioning (NF) pituitary neuroendocrine tumors (PitNETs) are non-resectable neoplasms associated to frequent relapse and significant comorbidities. As current treatments often fail against NF-PitNETs, identifying actionable therapeutic targets is essential. We focused on the angiopoietin-2 (Angpt2)/Tie2 axis, usually active in endothelial cells (ECs).Methods: ANGPT2 plasma levels in NF-PitNET patients and healthy controls were m...